Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
AssigneeNanoSystems L.L.C.
InventorsPranab Bagchi, Raymond P. Scaringe, H. William Bosch
Life of this patent
Estimating the term…
Loading patent…
AssigneeNanoSystems L.L.C.
InventorsPranab Bagchi, Raymond P. Scaringe, H. William Bosch
Estimating the term…
This invention describes the coprecipitation of nanoparticulate pharmaceutical agent dispersion via a process that comprises the dissolution of the said pharmaceutical agent in combination with a crystal growth modifier (CGM) in an alkaline solution and then neutralizing the said solution with an acid in the presence of suitable surface-modifying surface-active agent or agents to form a fine particle dispersion of the said pharmaceutical agent, followed by steps of diafiltration clean-up of the dispersion and then concentration of it to a desired level. This process of dispersion preparation leads to microcrystalline particles of Z-average diameters smaller than 400 nm as measured by photon correlation spectroscopy. Various modification of precipitation schemes are described, many of which are suitable for large-scale manufacture of these agent dispersions. It has been discovered that coprecipitation with CGM leads to smaller particle size compared to a case where precipitation is carried out using the pharmaceutical agent alone. Thus, this dispersion of instant invention is expected to have greater bioavailability. The CGM compound is a compound that has at least about 75% of its chemical structure identical to that of the pharmaceutical agent.
A process of forming nanoparticulate dispersions of diagnostic pharmaceutical agents comprising:
A process of preparing an aqueous dispersion of a diaganostic pharmaceutical agent comprising:
A process of preparing aqueous dispersions of a diagnostic pharmaceutical agent comprising:
A process of preparing aqueous dispersions of a diagnostic pharmaceutical agent comprising:
A composition comprising a nanoparticulate diagnostic pharmaceutical agent, a crystal growth modifier (CGM), surface modifying surface active agent or agents in water, wherein the CGM compound is structurally, on a molecular basis, at least 75% identical to the pharmaceutical agent compound.
Dependencies are inferred from the claim text.